NADAC acquisition cost data for MESALAMINE ER 0.375 GRAM CAP. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00093922489 | $0.8891 | 2022-12-21 | Rx |
| 00378137578 | $0.8891 | 2022-12-21 | Rx |
| 60687065032 | $0.8891 | 2022-12-21 | Rx |
| 60687065033 | $0.8891 | 2022-12-21 | Rx |
| 67877071712 | $0.8891 | 2022-12-21 | Rx |
| 68382045219 | $0.8891 | 2022-12-21 | Rx |
| 68682011320 | $0.8891 | 2022-12-21 | Rx |
| 70748021416 | $0.8891 | 2022-12-21 | Rx |
| 00093922489 | $0.8891 | 2022-12-21 | Rx |
| 00378137578 | $0.8891 | 2022-12-21 | Rx |
Generic: Mesalamine W/Cleansing Wipes | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $1.9M | 4,093 | 2,004 | $42.32 |
| 2020 | $1.6M | 3,509 | 1,622 | $59.38 |
| 2021 | $1.5M | 3,040 | 1,506 | $95.10 |
| 2022 | $1.2M | 2,356 | 1,159 | $87.26 |
| 2023 | $1.0M | 2,185 | 1,086 | $74.17 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| New York | $31.0M | 42,071 | 9,780 |
| California | $22.9M | 34,482 | 9,796 |
| Pennsylvania | $18.6M | 27,635 | 6,056 |
| Florida | $18.2M | 27,266 | 7,690 |
| Texas | $14.4M | 21,604 | 5,624 |
| New Jersey | $12.0M | 16,011 | 4,096 |
| Illinois | $11.7M | 14,991 | 3,888 |
| Michigan | $11.5M | 15,098 | 3,888 |
| Ohio | $10.3M | 15,235 | 3,664 |
| Massachusetts | $10.0M | 13,163 | 3,271 |
| North Carolina | $7.3M | 10,777 | 2,720 |
| Connecticut | $6.5M | 8,588 | 2,223 |
| Wisconsin | $6.2M | 8,465 | 2,074 |
| Georgia | $5.8M | 8,529 | 2,253 |
| Missouri | $5.5M | 8,135 | 1,972 |
| Washington | $5.5M | 7,692 | 1,928 |
| Virginia | $5.1M | 6,874 | 1,878 |
| Arizona | $4.8M | 6,255 | 1,821 |
| Indiana | $4.7M | 6,697 | 1,678 |
| Maryland | $4.5M | 5,595 | 1,617 |
| Minnesota | $4.2M | 5,093 | 1,300 |
| Tennessee | $4.0M | 5,910 | 1,512 |
| South Carolina | $3.5M | 5,112 | 1,371 |
| Colorado | $3.4M | 4,184 | 1,269 |
| Oregon | $3.2M | 4,457 | 1,188 |
| Kentucky | $2.9M | 4,367 | 1,076 |
| Puerto Rico | $2.9M | 5,287 | 1,089 |
| Alabama | $2.8M | 4,243 | 1,133 |
| Iowa | $2.4M | 3,732 | 808 |
| Oklahoma | $2.2M | 3,487 | 852 |
| Louisiana | $2.0M | 3,491 | 840 |
| Kansas | $1.9M | 3,285 | 687 |
| New Hampshire | $1.8M | 2,152 | 540 |
| Utah | $1.8M | 2,310 | 577 |
| Maine | $1.5M | 1,921 | 528 |
| Nebraska | $1.4M | 2,041 | 470 |
| Idaho | $1.4M | 1,882 | 473 |
| Nevada | $1.4M | 2,004 | 571 |
| Arkansas | $1.2M | 1,896 | 432 |
| Rhode Island | $1.2M | 1,950 | 482 |
| Delaware | $998.6K | 1,157 | 319 |
| New Mexico | $931.7K | 1,248 | 349 |
| West Virginia | $923.2K | 1,506 | 367 |
| Mississippi | $769.3K | 1,453 | 360 |
| South Dakota | $692.7K | 1,059 | 202 |
| Vermont | $670.0K | 716 | 199 |
| North Dakota | $603.8K | 870 | 209 |
| Hawaii | $567.1K | 837 | 270 |
| Alaska | $495.6K | 531 | 172 |
| District of Columbia | $480.9K | 529 | 185 |
| Montana | $446.3K | 654 | 170 |
| Wyoming | $283.7K | 353 | 95 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.